- Home
- LDP vs SCTX Comparison
LDP vs SCTX Comparison
Compare LDP & SCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LDP | SCTX |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 615.9M | 536.5M |
| IPO Year | N/A | 2026 |
Fundamental Metrics
Financial Performance| Metric | LDP | SCTX |
|---|---|---|
| Price | $18.62 | $15.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $57.00 |
| AVG Volume (30 Days) | 109.4K | ★ 415.3K |
| Earning Date | 01-01-0001 | 11-29-2026 |
| Dividend Yield | ★ 7.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.63 | $13.50 |
| 52 Week High | $22.05 | $39.60 |
Technical Indicators
Market Signals| Indicator | LDP | SCTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.27 | 33.52 |
| Support Level | N/A | $13.50 |
| Resistance Level | $20.93 | $22.07 |
| Average True Range (ATR) | 0.21 | 2.40 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 20.59 | 2.88 |
Price Performance
Historical ComparisonAbout LDP Cohen & Steers Limited Duration Preferred and Income Fund Inc.
Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.
About SCTX Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.